NEW YORK, November 6, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Covance Inc. (NYSE: CVD), Laboratory Corp. of America Holdings (NYSE: LH), Pfizer Inc. (NYSE: PFE) and AbbVie Inc. (NYSE: ABBV). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7736-100free.
--
Gilead Sciences, Inc. Research Reports
On October 28, 2014, Gilead Sciences, Inc. (Gilead) reported strong Q3 2014 and 9M 2014 earnings. During the quarter, the Company's total revenues improved by a staggering 117.1% YoY to $6.04 billion, led by product sales that witnessed a 120.3% YoY growth to reach $6.0 billion. The Company's Q3 2014 net income attributable to Gilead came in at $2.7 billion or $1.67 per diluted share, compared to net income of $788.6 million or $0.47 per diluted share in Q3 2013. The Company's Q3 2014 non-GAAP diluted EPS stood at $1.84. On average, 25 analysts polled by Thomson Reuters expected the Company to report Q3 2014 EPS (excluding special items) of $1.92 on revenue of $5.99 billion. The Company's 9M 2014 total revenues improved by 117.5% YoY to $17.6 billion, while net income attributable to Gilead came in at $8.6 billion, up 277.3% YoY. For full-year 2014, the Company expects net product sales between $22 billion and $23 billion and adjusted diluted EPS in the range of $0.63 - $0.66. The full research reports on Gilead are available to download free of charge at:
http://www.analystsreview.com/Nov-06-2014/GILD/report.pdf
--
Covance Inc. Research Reports
On November 3, 2014, Covance Inc. (Covance) and Laboratory Corporation of America® Holdings (LabCorp®) jointly announced that they have entered into a definitive agreement under which LabCorp will acquire Covance for cash and LabCorp shares currently valued at $105.12 per Covance share, or an equity value of approximately $6.1 billion and an enterprise value of approximately $5.6 billion. Further, the agreed price represents a 32% premium to its closing stock price of $79.90 on October 31, 2014 and a multiple of approximately 13.3 times of its EBITDA over the last 12 months through September 30, 2014. According to the terms of the transaction, which has been approved by the Boards of Directors of both companies, Covance shareholders will receive $75.76 in cash and 0.2686 LabCorp shares for each Covance share they own. The Company plans to close this transaction in Q1 2015, subject customary closing conditions. The full research reports on Covance are available to download free of charge at:
http://www.analystsreview.com/Nov-06-2014/CVD/report.pdf
--
Laboratory Corp. of America Holdings Research Reports
On October 28, 2014, Laboratory Corp. of America Holdings (Laboratory Corp) reported a 6.1% YoY growth in its Q3 2014 net sales that reached $1.55 billion, surpassing the Zacks consensus revenue estimate of $1.51 billion for the quarter. The Company's Q3 2014 net earnings attributable to Laboratory Corp came in at $137.2 million or $1.59 per diluted share, compared to net earnings of $148.3 million or $1.63 per diluted share in Q3 2013. The Company's Q3 2014 adjusted EPS stood at $0.81, surpassing the analyst estimate of $1.51 for the quarter, surveyed by Zacks Investment Research. The Company's 9M 2014 net sales improved 2.9% YoY to $4.5 billion, while net earnings attributable to Laboratory Corp declined 12.5% YoY to $391.6 million. The Company expects full-year 2014 revenue growth of approximately 3.0% over 2013 and adjusted EPS of $6.70 to $6.80. The full research reports on Laboratory Corp. are available to download free of charge at:
http://www.analystsreview.com/Nov-06-2014/LH/report.pdf
--
Pfizer Inc. Research Reports
On October 29, 2014, Pfizer Inc. (Pfizer) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of TRUMENBA® (meningococcal group B vaccine) for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age. The Company informed that approval of TRUMENBA is based on demonstration of immune response, as measured by serum bactericidal activity against four serogroup B strains representative of prevalent strains in the United States. The effectiveness of TRUMENBA against diverse serogroup B strains has not been confirmed. The full research reports on Pfizer are available to download free of charge at:
http://www.analystsreview.com/Nov-06-2014/PFE/report.pdf
--
AbbVie Inc. Research Reports
On October 31, 2014, AbbVie Inc. (AbbVie) reported its Q3 2014 and 9M 2014 financial results. The Company reported Q3 2014 net sales of $5.0 billion, up 7.8% YoY (Vs. Thomson Reuters consensus revenue estimate of $4.82 billion). The Company's Q3 2014 net earnings came in at $506 million or $0.31 per diluted share, compared to net earnings of $964 million or $0.60 per diluted share in Q3 2013. The Company reported Q3 2014 adjusted EPS of $0.89, surpassing average EPS estimate of $0.77 estimated by 11 analysts polled by Thomson Reuters. The Company reported 9M 2014 net sales of $14.5 billion, up 6.1% YoY, and net earnings of $2.6 billion, down 13.9% YoY. For full-year 2014, the Company expects diluted EPS in the range of $1.15 - $1.17. The full research reports on AbbVie are available to download free of charge at:
http://www.analystsreview.com/Nov-06-2014/ABBV/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
